United States v. Levin

973 F.2d 463, 1992 WL 186669
CourtCourt of Appeals for the Sixth Circuit
DecidedAugust 7, 1992
DocketNo. 91-5034
StatusPublished
Cited by59 cases

This text of 973 F.2d 463 (United States v. Levin) is published on Counsel Stack Legal Research, covering Court of Appeals for the Sixth Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
United States v. Levin, 973 F.2d 463, 1992 WL 186669 (6th Cir. 1992).

Opinions

KRUPANSKY, Senior Circuit Judge.

This is an appeal from a decision of the United States District Court for the Eastern District of Kentucky dismissing all but 15 counts of a 560-count indictment against the appellees herein with prejudice. The last 15 counts of the indictment were dismissed without prejudice. Defendants-appellees Richard D. Levin, M.D., P.S.C., Inc. (the “Eye Institute”) and Richard D. Levin, an individual, had been charged with multiple violations of 42 U.S.C. § 1395nn(b)(l)(B) (1983) (Medicare fraud); 18 U.S.C. § 287 (false claims); 18 U.S.C. § 1341 (mail fraud); and 18 U.S.C. § 1001 (false statements). Defendant-appellee Paul H. Sorg, an employee of the Eye Institute, was charged only in those counts alleging violations of 42 U.S.C. § 1395nn (Medicare fraud). The government has conceded that the false claims and mail fraud counts are legally dependent upon the Medicare fraud counts.

The predicate for the criminal charges against the appellees under 42 U.S.C. § 1395nn was a merchandising campaign created for the manufacturers of intraocu-lar lenses (IOL), which are inserted into the eye during cataract surgery to replace a removed diseased lens. The promotion was conducted in conjunction with various cooperating surgical supply companies. The targets of the promotion were medical doctors, primarily ophthalmologists, hospitals and surgical centers engaged in treating cataracts and performing surgical cataract implants.

The sales concept, once having been approved by the Department of Health and Human Services (HHS), Health Care Financing Administration (HCFA) and its duly designated carriers, i.e. Medicare, Blue Cross/Blue Shield, Prudential Insurance Co., et al., was actively inaugurated and aggressively implemented by a significant number of major IOL manufacturers and participating surgical supply companies through their representatives and sales personnel. In the instant case, the involved IOL manufacturers were American Medical Optics Co. (AMO) and Ipotex. The participating surgical supply company was Crocker Fels Corporation.

The thrust of the sales promotion, with minor variations, was essentially the same throughout the industry. The nucleus of the plan was an arrangement characterized as “bundling” which consisted of offering a free gift or premium in the form of disposable viscosurgical supplies such as plastic boots, gloves, gowns, masks, sutures, Heal-on syringes, and surgical knives consumed during a cataract surgery or a credit for the value of the premium with the purchase of each IOL. In the instant case, the value of the free premium disposable visco-surgical kit consumed during a single cataract surgical procedure was $97.50. The reasonable and customary charge by a provider hospital, surgical center, ophthalmologist and those similarly situated for an IOL was fixed by HCFA or its designated health care insurance carrier. A provider was entitled to reimbursement from Medicare or other designated health care carrier for the approved reasonable and customary cost of the IOL. In the instant case, the HCFA approved reasonable and customary charge for an AMO lens was $390.00. With the purchase of every AMO lens, the purchaser would receive free disposable viscosurgical supplies valued at $97.50 [465]*465from Crocker Fels Corporation or a credit in that amount against future purchases of such disposable surgical supplies consumed during a single cataract surgical implant.

Defendants were introduced and urged to participate in the sales campaign by Dale Schaefer, a manufacturer’s representative for AMO. Pursuant to typical sales arrangements that prevailed throughout the industry, appellees received disposable surgical supplies valued at $97.50, or a credit for that amount against future purchases of those items from Crocker Fels with each lens purchased from AMO for the HCFA approved reasonable and customary price of $390.00. Crocker Fels was reimbursed in that amount by the lens manufacturer, one of which, in the instant case was AMO. Generally, the cost of the disposable surgical supplies consumed during a surgical cataract implant exceeded $97.50.

At no time did defendants’ backcharge to Medicare or other HCFA designated health care insurance carrier exceed the HCFA reasonable and customary approved manufacturer’s price per IOL, in the instant case, $390.00 per AMO lens.

Preliminary to soliciting the participation of the professional medical community targeted for the sales promotion, certain IOL manufacturers sought and received approval of the proposal from the HCFA. In a series of official letters from HCFA “reimbursement specialists”, the proposed sales inducement campaign was sanctioned. Scott Levine, a reimbursement specialist for HCFA on December 10, 1985 stated that:

The customers of Pharmacia do not violate any HCFA regulation when they purchase a Viscolens (TM) or Viscosur-gery Pack, as long as they do not charge HCFA or the beneficiary any more for the Viscolens or the Viscosur-gery Pack than they previously charged for the IOL alone. That is, the physician should not charge for the items they received at no additional charge.

HCFA issued another similar letter on September 23, 1986, wherein it considered its approval of the suggested IOL inducement sales program as a public policy announcement:

[W]e believe that we have an obligation to the public to provide our opinion as to the propriety of certain charging arrangements. We have become aware that many different types of inducements are being used in the IOL supply industry, including the leasing of equipment at below market or otherwise subsidized rates in return for the purchase of IOLs, or the supply with the IOL of other additional items. At this time, we regard all such sales inducements in the same category for reimbursement purposes, that is, as long as the inducement is related to the item, and as long as there is no additional charge to the beneficiary of HCFA for the item, device or service, then there is no issue of reimbursement abuse.

In yet another letter, HCFA in addressing the question of free surgical supplies to induce the purchase of IOLs said:

To our knowledge, you would not be violating any HCFA reimbursement regulation by marketing the Viscolens (TM)/Viscosurgery (TM) Pack.
In addition, in our opinion, customers of Pharmacia would not be violating any HCFA reimbursement regulation by purchasing such a package. However, we would strongly advise any such customers not to charge a beneficiary or HCFA any more for the package than they had previously charged for the IOL alone.

Although defendants initiated no inquiry of their own concerning the legality of the sale campaign, it is apparent that HCFA approval of the “bundling arrangement” was circulated throughout the targeted professional medical community by manufacturers’ representatives and sales personnel.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

State v. Gatewood
2021 Ohio 3325 (Ohio Court of Appeals, 2021)
Hency v. St. Clair County
E.D. Michigan, 2019
United States v. McMichael
350 F. Supp. 3d 647 (W.D. Michigan, 2018)
United States v. Fitzgerald
366 F. Supp. 3d 903 (W.D. Michigan, 2017)
State v. Roller
2016 Ohio 8554 (Ohio Court of Appeals, 2016)
People of Michigan v. Dustin Lee MacLeod
Michigan Court of Appeals, 2016
United States v. Terry Honeycutt
816 F.3d 362 (Sixth Circuit, 2016)
United States v. John Lechner
806 F.3d 869 (Sixth Circuit, 2015)
United States v. Martinez-Mercado
145 F. Supp. 3d 150 (D. Puerto Rico, 2015)
United States v. Valle-Fuentes
143 F. Supp. 3d 24 (D. Puerto Rico, 2015)
United States v. Williams
116 F. Supp. 3d 664 (E.D. North Carolina, 2015)
State of Minnesota v. Christian Phillip Oberender
Court of Appeals of Minnesota, 2014
United States v. Hemme
987 F. Supp. 2d 940 (D. Minnesota, 2013)
United States v. George Dodson, III
519 F. App'x 344 (Sixth Circuit, 2013)
United States v. Duval
865 F. Supp. 2d 803 (E.D. Michigan, 2012)
United States v. Huet
665 F.3d 588 (Third Circuit, 2012)
United States v. Weaver
659 F.3d 353 (Fourth Circuit, 2011)
United States v. Nitschke
843 F. Supp. 2d 4 (District of Columbia, 2011)
Ankrom v. State
152 So. 3d 373 (Court of Criminal Appeals of Alabama, 2011)
State v. Worley
102 So. 3d 408 (Court of Criminal Appeals of Alabama, 2009)

Cite This Page — Counsel Stack

Bluebook (online)
973 F.2d 463, 1992 WL 186669, Counsel Stack Legal Research, https://law.counselstack.com/opinion/united-states-v-levin-ca6-1992.